Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Kingkilleron May 24, 2018 1:03pm

127 Views

Post# 28076048

RE:RE:Looking forward to seeing ATB 428 & 429 added to our

Crazy how its still below .40$. Loaded more this morning. Glta

StrikingMoose wrote: With cash on hand and cash coming in from warrants they should easily be able to afford pre clinicals on all their pipeline drugs now, maybe even their IBS drugs. When phase 2b pain results come in and are good with a cash injection from a larger company or partnership to fund further research they could potentially develop all 5 drugs with the hopes a couple would make to market. Amazing.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?